BRAF inhibitor unveils its potential against advanced melanoma

Adina Vultur1, Jessie Villanueva, Meenhard Herlyn

  • 1The Wistar Institute, Philadelphia, PA 19104, USA.

Cancer Cell
|October 19, 2010
PubMed

Insights

Targeted therapy for advanced melanoma shows promise. Recent studies validate PLX4032, a BRAF kinase inhibitor, for treating melanomas with BRAF-activating mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • Advanced metastatic melanoma often exhibits unresponsiveness to conventional therapies.
  • BRAF-activating mutations are identified in approximately 50% of human melanomas, presenting a key therapeutic target.

Discussion:

  • Two recent publications highlight the efficacy of the mutant BRAF kinase inhibitor PLX4032.
  • These studies validate the concept of oncogene-targeted therapy for melanoma treatment.

Key Insights:

  • PLX4032 effectively targets mutant BRAF kinases in melanoma.
  • The findings support the development of precision medicine approaches for melanoma.

Outlook:

  • Further research into BRAF inhibitors like PLX4032 is warranted for advanced melanoma.
  • Oncogene-targeted therapy represents a significant advancement in melanoma treatment strategies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...